

OTHER EXAMPLES FOR VICTOR PLATFORM

In addition to the SHEP trial, we also use the VICTOR platform for another three trials:

- (1) **ALLHAT** – Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
- (2) **ACCORD** – Action to Control Cardiovascular Risk in Diabetes Trial
- (3) **AIMHIGH** – Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglyceride and Impact on Global Health Outcomes

For each trial, we first use feasibility checklist and questionnaire to determine whether the VICTOR platform can be used to estimate the expected value of perfect information (EVPI) and the expected value of sample information (EVSI). If so, we will list the parameters input and results, and also describe challenges and potential solutions to obtain these parameters.

Example 3 - AIM-HIGH

The aim of the AIM-HIGH trial was to test the efficacy of extended-release niacin on patients with atherosclerotic cardiovascular (CV) disease. Participants were randomized to receive either niacin plus simvastatin or placebo plus simvastatin. The primary endpoint of the study was composition of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, hospitalization for acute coronary syndrome, symptom-driven coronary or cerebral revascularization. However, the VICTOR platform was not applicable for a study that included hospitalization as the endpoint. Therefore, users will see the following message from VICTOR feasibility check page if they choose “none of the above” for their primary endpoint.


“Right Now, VICTOR platform only caters to the four primary endpoints listed above.

Therefore, it is not suitable to use for your research “

Applying Feasibility Checklist

FEASIBILITY FACTOR	FEASIBILITY QUESTION	EXAMPLE – Aim-HIGH	
STUDY POPULATION:	Is the condition of interest for your study population listed?	Patients with cardiovascular disease	<input type="checkbox"/> Y/ <input type="checkbox"/> N
STUDY TYPE:	Is your proposed study design listed?	Niacin+simvastatin v.s. placebo+simvastatin	<input type="checkbox"/> Y/ <input type="checkbox"/> N
ENDPOINTS:	Is your proposed primary study endpoint listed?	Composite of CHD death, non-fatal MI, stroke, hospitalization of acute coronary syndrome, symptom driven coronary or cerebral revascularization	<input type="checkbox"/> Y/ <input checked="" type="checkbox"/> N
INTERVENTION EFFECTS:	Can the effect of the intervention in your proposal be expressed using one of the options listed?	No results for hospitalization of acute coronary syndrome, symptom driven coronary or cerebral revascularization	<input type="checkbox"/> Y/ <input checked="" type="checkbox"/> N
BACKGROUND CLINICAL DATA FOR CONTROL GROUP, BY ENDPOINT	Do you have listed data on the control group for the primary endpoint?		
BACKGROUND CLINICAL DATA ON INTERVENTION EFFECTS, BY ENDPOINT	Do you have listed data on selected intervention effects?		

Feasibility questionnaire

Resize font: 

VICTOR Feasibility Check

Researchers intending to estimate the value of their proposed research can use this checklist to see if they have all the necessary information to use the VICTOR platform. The necessary set of information consists of a minimum set of study characteristics and data availability.

CONDITION OF INTEREST Is your study related to cardiovascular diseases? <i>* must provide value</i>	<input checked="" type="radio"/> Yes <input type="radio"/> No	reset
STUDY TYPE Is your proposed study design a comparative 2 arm study (e.g. clinical trial or other research design)? <i>* must provide value</i>	<input checked="" type="radio"/> Yes <input type="radio"/> No	reset
PRIMARY ENDPOINT Is the primary endpoint in your proposed study any one of the following? <i>* must provide value</i>	<input type="radio"/> All-cause mortality <input type="radio"/> Stroke (fatal and non-fatal) <input type="radio"/> MI (fatal and non-fatal) <input type="radio"/> MACE (CVD mortality, non-fatal stroke and MI) <input checked="" type="radio"/> None of the above	reset

RIGHT NOW, VICTOR PLATFORM ONLY CATERS TO THE FOUR PRIMARY ENDPOINTS LISTED ABOVE.

THEREFORE, IT IS NOT SUITABLE TO USE FOR YOUR RESEARCH.